Rituxan (rituximab) / Zenyaku Holdings, Biogen, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

172 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
REMoDL-A, NCT04546620: Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
453
Europe
R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, R-CHOP + acalabrutinib, Acalabrutinib
University Hospital Southampton NHS Foundation Trust, AstraZeneca
Diffuse Large B Cell Lymphoma
01/27
07/27
NCT05280626: First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Not yet recruiting
2
100
NA
Sintilimab, Cyclophosphamide, Doxorubicin, Oncovin, Prednisolone, Rituximab
Innovent Biologics (Suzhou) Co. Ltd.
Diffuse Large B-Cell Lymphoma
12/25
12/26
NCT05783609: Epcoritamab and Rituximab for First-line Follicular Lymphoma

Recruiting
2
35
US
Epcoritamab, DuoBody-CD3xCD20, GEN3013, Rituximab, Rituxan, MabThera
Reid Merryman, MD, Genmab, AbbVie
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
01/26
02/29
waveLINE-007, NCT05406401 / 2021-005861-41: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Recruiting
2
60
Europe, Canada, RoW
Zilovertamab Vedotin, MK-2140, VLS-101, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab, RITUXAN®, Rituximab Biosimilar, TRUXIMA®, Prednisone, Prednisolone
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Lymphoma, Large B-Cell, Diffuse (DLBCL)
01/26
01/26
NCT05600686: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Recruiting
2
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
Joseph Tuscano, National Cancer Institute (NCI), ADC Therapeutics S.A.
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
02/26
02/28
MTR², NCT05583071: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Not yet recruiting
2
20
Europe
Tafasitamab, Lenalidomide, Rituximab, Methotrexate
University of Cologne, Incyte Corporation
Non-Hodgkin Lymphoma
02/27
04/27
CARAMEL, NCT05004064: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

Not yet recruiting
2
26
NA
Acalabrutinib, Rituximab
University College, London, AstraZeneca
Mantle Cell Lymphoma
05/26
05/26
BeliVeR, NCT05069051: Belimumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
2
120
Europe
Belimumab 200 MG/ML [Benlysta], standard of care
University Hospital Tuebingen, GlaxoSmithKline
Chronic Lymphoid Leukemia in Relapse
07/26
07/27
NCT05800366: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, Polatuzumab, Polatuzumab vedotin, DCDS4501S, RG7596, Rituximab, Rituxan, Doxorubicin Hydrochloride, Hydroxydaunomycin, Cyclophosphamide, Cytophosphane, Cytoxan, Prednisone, Prednisolone, Methylprednisolone
Jennifer Crombie, MD, Genentech, Inc.
Lymphoma, Lymphoma, Large B-Cell, Diffuse
09/26
09/29
VIWA-1, NCT05099471: Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Not yet recruiting
2
80
NA
Venetoclax; Rituximab, Venetoclax / Rituximab, DRC, Dexamethasone / Rituximab / Cyclophosphamide
University of Ulm, Ludwig-Maximilians - University of Munich, Zentrum für Klinische Studien Ulm, AbbVie, Pfizer, University Hospital Schleswig-Holstein, Campus Kiel
Waldenstrom Macroglobulinemia
10/27
10/32
NCT05065554: ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Recruiting
2
33
US
Acalabrutinib, Calquence, Rituximab, Rituxan
Shayna Sarosiek, MD, AstraZeneca
IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
12/26
10/28
NCT06046248: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Recruiting
2
25
US
Belumosudil, Rituximab
Northside Hospital, Inc., Sanofi
Chronic Graft Versus Host Disease
12/26
12/27
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
TOP-FLOR, NCT05788081: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Recruiting
2
40
RoW
golcadomide, BMS-986369, CC-99282, Nivolumab 10 MG/ML, Opdivo, Rituximab, Mabthera
Olivia Newton-John Cancer Research Institute, Austin Health, Grampians Health, Fiona Stanley Hospital, Eastern Health, Barwon Health, Bristol-Myers Squibb
Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV
01/27
06/27
ACRUE, NCT05952024: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Not yet recruiting
2
80
NA
Acalabrutinib, CALQUENCE®, Rituximab
AstraZeneca
Diffuse Large B-Cell Lymphoma
09/27
09/27
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
NCT05998642: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting
2
30
Canada
Methotrexate, Rituximab (where available), Ibrutinib
Canadian Cancer Trials Group, Janssen Inc.
Non-hodgkin Lymphoma
05/28
12/28
ZEBRA, NCT05635162: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Recruiting
2
50
Europe
Zanubrutinib, Rituximab
University College, London, BeiGene
Mantle Cell Lymphoma
10/28
10/28
TrAVeRse, NCT05951959: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Hourglass Dec 2023 - Dec 2023 : Data from TrAVeRse trial in patients with treatment- naïve mantle cell lymphoma at ASH 2023
Hourglass Jan 2020 - Dec 2020 : From ACE-CL-208 trial in r/r CLL
Recruiting
2
100
Europe, Canada, US, RoW
Acalabrutinib, Acalabrutinib, CALQUENCE, Venetoclax, Rituximab
AstraZeneca
Mantle Cell Lymphoma (MCL)
01/29
01/29
EPCORE NHL-5, NCT05283720 / 2021-005725-24: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Recruiting
2
394
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013;, Lenalidomide, Ibrutinib, Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, Venetoclax, Venclexta;, ABT-199, GDC-0199, CC-99282
Genmab, AbbVie
Non-Hodgkin Lymphoma
11/32
11/32
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
NCT02158091: A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Active, not recruiting
1b/2
32
US
IPI-145, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan
Dana-Farber Cancer Institute, Secura Bio, Inc.
Chronic Lymphocytic Leukemia
10/17
07/25
2013-002711-94: HOVON 124 WM study: A trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.

Ongoing
1/2
72
Europe
MLN9708 4 mg, rituximab, MLN9708 3 mg, MLN9708 2,3 mg, Capsule, hard, Concentrate for solution for infusion, Solution for injection, Mabthera 100mg/10ml, Mabthera 500mg/50ml, Mabthera s.c.
HOVON Foundation, Dutch Cancer Society, Millennium, Roche Nederland BV, Roche Belgium, Roche (Hellas) S.A.
Waldenström's macroglobulinemia, Morbus Waldenström, Diseases [C] - Cancer [C04]
 
 
2019-000111-84: A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin Lymphoma Studio di acalabrutinib da solo o in associazione con Rituximab e Lenalidomidein soggetti con linfoma non Hodgkin a cellule B

Not yet recruiting
1/2
120
Europe
Acalabrutinib, Rituximab, Revlimid®, Revlimid, [ACP-196], [Rituximab], [Revlimid®], [Revlimid], Capsule, hard, Concentrate for solution for infusion, MabThera, Revlimid®
ACERTA PHARMA BV, Acerta Pharma BV
B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, Diseases [C] - Cancer [C04]
 
 
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02481310: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
1/2
38
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ixazomib Citrate, MLN-9708, MLN9708, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar BI 695500, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, RTXM83, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, HYDROCORTISONE, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Northwestern University, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc.
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
09/20
07/24
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
PARADIGME, NCT01796171 / 2011-000033-36: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

Hourglass Jul 2018 - Dec 2018 : Completion of enrollment in pivotal P2 PARADIGME trial
Checkmark LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Nov 2018 - Nov 2018: LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Hourglass Oct 2016 - Dec 2016 : Dose escalation in arm 1 and either arm 3 or 4 of P1/2 Lymrit 37-01 trial for FL
Hourglass Oct 2016 - Dec 2016 : SRC review of data from arms 3 and 4 of P1/2 Lymrit 37-01 trial for FL
More
Completed
1/2
191
Europe, Canada, US, RoW
10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin, 40 mg lilotomab, 100 mg/m2 lilotomab, 60 mg/m2 lilotomab, Rituximab, 12.5 mBq/kg Betalutin
Nordic Nanovector, ICON Clinical Research
Non-Hodgkin Lymphoma, Follicular Lymphoma
10/22
10/22
Epi-RCHOP, NCT02889523 / 2016-001499-31: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Calendar Jan 2023 - Dec 2024: Data from P1b/2 trial for DLBCL and follicular lymphoma
Checkmark Initial combination data
Dec 2018 - Dec 2018: Initial combination data
Not Appicable May 2018 - May 2018 : Epi-RCHOP trial in 1L DLBCL [Trial suspended]
Checkmark Transition into P2 in P1/2 Epi-RCHOP trial in frontline DLBCL
More
Active, not recruiting
1/2
214
Europe
Tazemetostat, EPZ-6438, Rituximab, Mabthera, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone
The Lymphoma Academic Research Organisation, Epizyme, Inc.
Lymphoma, DLBCL, Follicular Lymphoma
01/23
04/26
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
TAK-981-1501, NCT04074330: A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Terminated
1/2
38
Europe, Canada, Japan, US, RoW
TAK-981, Rituximab
Takeda
Lymphoma, Non-Hodgkin
04/23
04/23
2020-003946-36: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Lymphoma

Not yet recruiting
1/2
180
Europe
NA, Rituximab, TAK-981, Concentrate for solution for infusion, MabThera
Takeda Development Center Americas, Inc., TAKEDA DEVELOPMENT CENTER AMERICAS INC., Takeda Development Center Americas, Inc. (TDC Americas)
Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma, Lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
08/24
03/25
NCT01484093: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Completed
1/2
96
US
R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR., HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE (ASCR)Patients admitted to the hospital for high dose chemotherapy. The anticipated length of, stay is 3-4 weeks. 14 days ± 1 day following the administration of the therapeutic dose of Iodine 131 I, Tositumomab, patients will be admitted for high-dose chemotherapy. BEAM, will be administered
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
08/23
08/23
NCT02632396: Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Active, not recruiting
1/2
12
US
Ixazomib, Ninlaro, MLN9708, Ixazomib Citrate, Rituximab, Rituxan, MabThera, Chimeric Anti-CD20 Antibody
Emory University, Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Mantle Cell Lymphoma
08/23
08/24
ACE-LY-003, NCT02180711: Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Hourglass Feb 2024 - Jun 2024 : Results from ACE-LY-003 trial for r/r follicular lymphoma
Hourglass Jul 2023 - Sep 2023 : Last patient dosing of P1 ACE-LY-003 trial for relapsed/refractory follicular lymphoma
Active, not recruiting
1/2
113
Europe, Canada, US
acalabrutinib, ACP-196, rituximab (IV), Lenalidomide
Acerta Pharma BV, AstraZeneca
Non Hodgkin Lymphoma
08/23
12/28
NCT02957019 / 2014-001949-25: A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
1/2
6
Europe
L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Philogen S.p.A.
Diffuse Large B-cell Lymphoma (DLBCL)
09/23
09/23
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Completed
1/2
117
Europe, US, RoW
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
10/23
10/23
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
01/24
07/25
NCT05577364: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Recruiting
1/2
54
RoW
Selinexor, exportin 1 (XPO1) inhibitor, R-CHOP Protocol, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Sun Yat-sen University, Fudan University, Antengene Corporation
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
12/24
02/26
BRUIN, NCT03740529 / 2018-003340-24: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Active, not recruiting
1/2
860
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
09/27
01/28
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
NCT05551936: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Recruiting
1/2
42
US
Bendamustine, Bendeka, Treanda, Rituximab, Rituxan, Tazemetostat, Tazverik
Vaishalee Kenkre, Epizyme, Inc., University of Wisconsin, Madison
Follicular Lymphoma
08/24
05/25
NCT03129828 / 2015-003429-32: Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

Active, not recruiting
1/2
34
Europe
Ibrutinib and Bortezomib + R-CHOP, Ibrutinib (Imbruvica®), Bortezomib (Velcade®)
Prof. Dr. Clemens Schmitt, Charite University, Berlin, Germany, Janssen-Cilag Ltd.
Diffuse Large B Cell Lymphoma
06/24
01/25
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT02953509 / 2016-003408-29: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Checkmark Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Jan 2023 - Jan 2023: Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Hourglass Apr 2020 - Sep 2020 : Safety and efficacy data from P1b trial in combination with rituximab for DLBCL
Checkmark In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
Jun 2019 - Jun 2019: In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
More
Terminated
1/2
178
Europe, US, RoW
Magrolimab, Hu5F9-G4, Rituximab, RITUXAN®, MabThera, Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®
Gilead Sciences, The Leukemia and Lymphoma Society
Non Hodgkin Lymphoma
03/24
03/24
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
06/25
09/29
GO40516, NCT03671018 / 2018-001141-13: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Dec 2021 - Dec 2021: Data from trial in combination with polatuzumab vedotin for DLBCL at ASH 2021
Checkmark Data from trial in combination with polivy for r/r NHL
Jun 2021 - Jun 2021: Data from trial in combination with polivy for r/r NHL
Checkmark Preliminary data from trial in combination with Polivy for NHL at ASH 2020
More
Active, not recruiting
1/2
422
Europe, Canada, US
Mosunetuzumab (IV), BTCT4465A, Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
01/24
07/25
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
108
US
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Artiva Biotherapeutics, Inc.
Non Hodgkin Lymphoma
11/24
11/24
NCT05267054: Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Recruiting
1/2
80
RoW
Ociperlimab, BGB-A1217, Tislelizumab, BGB A317, Rituximab
BeiGene
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
 
 
COMPARE, NCT06475495: Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

Not yet recruiting
1/2
13
NA
KYV101, Rituximab (active comparator)
Charite University, Berlin, Germany, Kyverna Therapeutics
Rheumatoid Arthritis
03/27
03/27
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting
1/2
123
RoW
APG-2575, Rituximab, Ibrutinib
Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/25
NCT05615974: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Suspended
1/2
145
RoW
LM101, Toripalimab, Rituximab, Envafolimab
LaNova Medicines Limited
Malignant Tumors
12/24
08/25
EPCORE NHL-3, NCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

Active, not recruiting
1/2
102
Japan
epcoritamab (monotherapy), GEN3013, DuoBody®-CD3xCD20, EPKINLY™, epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, gemcitabine and oxaliplatin, Gemox, epcoritamab (maintenance), rituximab and lenalidomide, R2
Genmab, AbbVie
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
12/24
12/24
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Recruiting
1/2
84
RoW
ATG-010, Selinexor, Lenalidomide, Rituximab
Antengene Corporation
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
03/25
06/25
J-MIND, NCT04661007: To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Recruiting
1/2
65
Japan
tafasitamab, INCMOR00208, MOR00208, Xmab5574, lenalidomide, parsaclisib, R-CHOP
Incyte Biosciences Japan GK
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
05/25
07/26
17-BI-1206-02, NCT03571568 / 2018-000444-26: A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
98
Europe, US, RoW
BI-1206, Rituximab
BioInvent International AB
Indolent B-Cell Non-Hodgkin Lymphoma
09/25
09/25
NCT05683171: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Recruiting
1/2
60
US
Rituximab, Rituxan, Lenalidomide, CC-5013, Revlimid™, Valemetostat
M.D. Anderson Cancer Center, Daiichi Sankyo
Lymphoma
09/25
09/25
NCT06119685: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting
1/2
128
US
IDP-023, Rituximab, Rituxan, Daratumumab, Darzalex, Interleukin-2, Proleukin, Cyclophosphamide, Fludarabine, Mesna
Indapta Therapeutics, INC.
NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
12/25
12/29
CC-99282-NHL-001, NCT03930953: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting
1/2
438
Europe, Canada, US, RoW
CC-99282, BMS-986369, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Celgene
Lymphoma, Non-Hodgkin
04/26
04/27
NCT05698147: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Recruiting
1/2
30
RoW
Selinexor, ATG-010, Rituximab, RiTUXimab Injection, Methotrexate, MTX
Tong Chen, MD, Antengene Corporation
Central Nervous System Lymphoma
06/26
12/26
NCT02315326: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Recruiting
1/2
109
US
Ibrutinib, Imbruvica™, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC., Janssen Biotech, Inc.
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
12/26
12/26
NCT05900401: Delayed Tolerance Through Mixed Chimerism

Recruiting
1/2
20
US
Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine, Cyclophosphamide, Rituximab, Siplizumab
Massachusetts General Hospital, Ossium Health, Inc., ITB-Med LLC
Kidney Failure, Kidney Transplant; Complications, Chimera
12/28
12/30
iMATRIX GLO, NCT05533775 / 2021-006326-48: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
65
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
10/27
10/27
NCT06090539: A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Recruiting
1/2
273
Europe, US
BMS-986458, Rituximab
Bristol-Myers Squibb
Relapsed/Refractory Non-Hodgkin Lymphoma
10/27
10/28
NCT03952637: A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Recruiting
1/2
45
US
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
National Human Genome Research Institute (NHGRI), Sio Gene Therapies
Lysosomal Diseases, Gangliosidosis, GM1
01/28
01/28
CD2 SCD, NCT06078696: Siplizumab for Sickle Cell Disease Transplant

Recruiting
1/2
18
US
Siplizumab, TCD601 (Siplizumab), Exchange Transfusion, Total Body Irradiation, TBI, Stem Cell Infusion, Cyclophosphamide 50mg, Cytoxan, Cytoxan Lyophilized, Mesna, Mesnex, Sirolimus Oral Tablet, Rapamycin, Rapamune, Rituximab or Biosimilar, Riabni, Rituxan, Ruxience, Truxima
Markus Mapara, ITB-Med LLC
Anemia, Sickle Cell
07/28
07/29
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
Dec 2022 - Dec 2022: Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29
PROPEL, NCT04127578: Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation

Recruiting
1/2
20
US, RoW
LY3884961, Methylprednisolone, Sirolimus
Prevail Therapeutics, Eli Lilly and Company
Parkinson Disease
06/29
06/29
EPCORE CLL-1, NCT04623541 / 2020-000848-57: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Checkmark Data from RS expansion cohort of EPCORE CLL-1 trial for r/r DLBCL at ASH 2022
Dec 2022 - Dec 2022: Data from RS expansion cohort of EPCORE CLL-1 trial for r/r DLBCL at ASH 2022
Checkmark Preliminary results from trial for CLL at ASH 2021
Dec 2021 - Dec 2021: Preliminary results from trial for CLL at ASH 2021
Recruiting
1/2
184
Europe, US, RoW
Epcoritamab, EPKINLY™, GEN3013, DuoBody®-CD3xCD20, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide
Genmab, AbbVie
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome
06/29
08/29
FTD-GRN, NCT04408625: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations

Recruiting
1/2
23
Europe, US, RoW
LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone
Prevail Therapeutics, Eli Lilly and Company
Frontotemporal Dementia
08/29
08/29
 

Download Options